DrugPatentWatch Database Preview

CAPRELSA Drug Profile

« Back to Dashboard

When do Caprelsa patents expire, and when can generic versions of Caprelsa launch?

Caprelsa is a drug marketed by Genzyme Corp and is included in one NDA. There are four patents protecting this drug.

This drug has one hundred and thirty-nine patent family members in forty-three countries.

The generic ingredient in CAPRELSA is vandetanib. Two suppliers are listed for this compound. Additional details are available on the vandetanib profile page.

Summary for CAPRELSA

International Patents:	139
US Patents:	4
Applicants:	1
NDAs:	1
Suppliers / Packagers:	2
Bulk Api Vendors:	100
Clinical Trials:	15
Patent Applications:	3,826
Formulation / Manufacturing:	see details
Drug Prices:	Drug price information for CAPRELSA
Prior Art and Litigation Support	Order Prior Art and Litigation support for CAPRELSA
DailyMed Link:	CAPRELSA at DailyMed

Generic Entry Opportunity Date for CAPRELSA

NDA:

022405

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for CAPRELSA

Drug Class	Kinase Inhibitor
Mechanism of Action	Protein Kinase Inhibitors P-Glycoprotein Inhibitors Organic Cation Transporter 2 Inhibitors

Synonyms for CAPRELSA

(4-Bromo-2-fluoro-phenyl)-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinazolin-4-yl]-amine

2ivu

338992-00-0

4-(4-Bromo-2-fluoroanilino)-6-methoxy- 7-[(1-methylpiperidin-4-yl)methoxy]quinazoline

4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-yl)methoxyquinazoline

4-(4-bromo-2-fluoroanilino)-6-methoxy-7-(1-methylpiperidin-4-ylmethoxy)quinazoline

4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline

4-[(4-Bromo-2-fluorophenyl)amino]-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazoline

4-BROMO-2-FLUORO-N-[(4E)-6-METHOXY-7-[(1-METHYLPIPERIDIN-4-YL)METHOXY]QUINAZOLIN-4(1H)-YLIDENE]ANILINE

4-Quninazolinamine, N-(4-bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-

443913-73-3

6-[(4R,5S,6S,7R)-4,7-dibenzyl-3-(5-carboxypentyl)-5,6-dihydroxy-2-oxo-1,3-diazepan-1-yl]hexanoic acid

68541-EP2298768A1

68541-EP2308855A1

913V733

A25648

AB0008635

AB01273969_04

AB01273969-01

AB01273969-02

AB1008463

ABP000873

AC-5251

AC1MIWRU

AJ-45811

AKOS015902350

AN-3469

ANW-61824

AOB87780

AS-11067

AZD-6474

BC224441

BCP01925

BCPP000023

BDBM21

BRD-K77625799-001-01-0

C22H24BrFN4O2

Caprelsa (TN)

CAS-443913-73-3

CH 331

CHEBI:49960

CHEMBL24828

cid_3081361

CS-0130

CTK8B9016

D06407

DB05294

DMPC Cyclic Urea 1

DSSTox_CID_26681

DSSTox_GSID_46681

DSSTox_RID_81816

DTXSID1046681

EN002713

EX-A422

F9995-0087

FT-0656736

GNF-PF-2188

GTPL5717

HMS3244K03

HMS3244K04

HMS3244L03

HMS3654E11

HSDB 8198

HY-10260

I14-1942

KB-34269

Kinome_3316

LS-184394

MCULE-4705827953

MLS006011672

MolPort-005-942-399

N-(4-bromo-2-fluoro-phenyl)-6-methoxy-7-[(1-methyl-4-piperidyl)methoxy]quinazolin-4-amine

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine

N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine

N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine

NCGC00167513-01

NCGC00167513-02

NCGC00167513-03

NCGC00167513-04

NCGC00167513-09

NSC-744325

NSC-760766

NSC744325

NSC760766

PubChem22460

QCR-37

Quinazolin-4-amine, N-(4-bromo-2-fluorophenyl)-6-mthoxy-7-[(1-methyl-4-piperidinyl)methoxy]-

RS0036

RT-016214

s1046

SB16919

SC-23330

SCHEMBL9044

SMR002530472

SR-00000000462

SR-00000000462-2

ST2407381

SW218092-2

SYN1090

Tox21_112511

Tox21_112511_1

UHTHHESEBZOYNR-UHFFFAOYSA-N

UNII-YO460OQ37K

V-9402

Vandetanib

Vandetanib (JAN/USAN/INN)

Vandetanib (Zactima)

vandetanib (zd6474)

Vandetanib [INN]

Vandetanib [USAN:INN:BAN:JAN]

Vandetanib, Zactima, ZD6474

Vandetanib;7-((4-aminocyclohexyl)methoxy)-N-(4-bromo-2-fluorophenyl)-6-methoxyquinazolin-4-amine

Vandetanib(Zactima),ZD6474/

Vandetinib

W-5356

YO460OQ37K

Zactima

ZD 6474

ZD-64

ZD-6474

ZD6474

ZINC53683345

US Patents and Regulatory Information for CAPRELSA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011		RX	Yes	No
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-002	Apr 6, 2011		RX	Yes	Yes			Y	Y
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011		RX	Yes	No			Y	Y
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-002	Apr 6, 2011		RX	Yes	Yes			Y	Y
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011		RX	Yes	No			Y
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011		RX	Yes	No			Y	Y

Expired US Patents for CAPRELSA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-001	Apr 6, 2011
Genzyme Corp	CAPRELSA	vandetanib	TABLET;ORAL	022405-002	Apr 6, 2011

International Patents for CAPRELSA

Country	Patent Number	Estimated Expiration
Slovakia	287401
Russian Federation	2383343
Slovakia	283175
South Korea	20070034499
Spain	2185999
Switzerland	0929530

Supplementary Protection Certificates for CAPRELSA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1244647	SPC/GB12/036	United Kingdom		PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/11/749/001 20120217; UK EU/1/11/749/002 20120217
1244647	PA2012015,C1244647	Lithuania		PRODUCT NAME: VANDETANIBUM; REGISTRATION NO/DATE: EU/1/11/749/001, 2012 02 17 EU/1/11/749/002 20120217
1244647	2012/029	Ireland		PRODUCT NAME: VANDETANIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/11/749/001-002 20120217
1244647	122012000001	Germany		PRODUCT NAME: IPILIMUMAB; REGISTRATION NO/DATE: EU/1/11/698/001-002 20110713
1244647	2012C/036	Belgium		PRODUCT NAME: VANDETANIB OU L'UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLE; AUTHORISATION NUMBER AND DATE: EU/1/11/749/001 20120221
1244647	C01244647/01	Switzerland		FORMER OWNER: ASTRAZENECA AB, SE